Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 406

1.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 May 25. pii: S1083-8791(19)30332-5. doi: 10.1016/j.bbmt.2019.05.021. [Epub ahead of print]

PMID:
31136799
2.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.

3.

Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD.

Rashidi A, Shanley R, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2019 Mar;54(3):490-493. doi: 10.1038/s41409-018-0331-1. Epub 2018 Aug 31. No abstract available.

PMID:
30171221
4.

Defining Competency to Empower Blood and Marrow Transplant and Cellular Immunotherapy Quality Management Professionals in Healthcare.

Repaczki-Jones R, Hrnicek AK, Heissenbuttel A, Devine S, Fernandez H, Anasetti C.

Biol Blood Marrow Transplant. 2019 Jan;25(1):179-182. doi: 10.1016/j.bbmt.2018.08.017. Epub 2018 Aug 21.

PMID:
30138698
5.

Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Br J Haematol. 2018 Sep;182(6):887-894. doi: 10.1111/bjh.15492. Epub 2018 Jul 13.

PMID:
30004111
6.

Hepatic veno-occlusive disease following sirolimus-based immune suppression.

Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J.

Bone Marrow Transplant. 2019 Jan;54(1):85-89. doi: 10.1038/s41409-018-0233-2. Epub 2018 Jun 12.

PMID:
29895929
7.

Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases.

Markow M, Mirza AS, Perez L, Shao H, Horna P, Anasetti C, Sokol L, Hussaini MO.

Case Rep Hematol. 2018 Feb 28;2018:9191582. doi: 10.1155/2018/9191582. eCollection 2018.

8.

Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.

Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C.

Bone Marrow Transplant. 2018 Nov;53(11):1434-1444. doi: 10.1038/s41409-018-0163-z. Epub 2018 Apr 18.

PMID:
29670210
9.

Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples.

Rashidi A, Shanley R, Yohe SL, Thyagarajan B, Curtsinger J, Anasetti C, Waller EK, Miller JS, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2018 Aug;53(8):1069-1071. doi: 10.1038/s41409-018-0127-3. Epub 2018 Mar 7. No abstract available.

PMID:
29515246
10.

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1582-1587. doi: 10.1073/pnas.1712452115. Epub 2018 Jan 30.

11.

Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.

Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J.

Br J Haematol. 2018 Mar;180(6):854-862. doi: 10.1111/bjh.15105. Epub 2018 Jan 18.

PMID:
29345306
12.

Off-the-shelf TCR for graft-versus-leukemia without GVHD.

Locke FL, Anasetti C.

Blood. 2018 Jan 4;131(1):5-7. doi: 10.1182/blood-2017-11-812990. No abstract available.

13.

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.

Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JLM, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C.

Haematologica. 2018 Mar;103(3):531-539. doi: 10.3324/haematol.2017.171199. Epub 2017 Dec 14.

14.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

15.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):400-405. doi: 10.1016/j.bbmt.2017.09.022. Epub 2017 Oct 13.

16.

The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients.

Hoogland AI, Nelson AM, Small BJ, Hyland KA, Gonzalez BD, Booth-Jones M, Anasetti C, Jacobsen PB, Jim HSL.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1974-1979. doi: 10.1016/j.bbmt.2017.08.006. Epub 2017 Aug 7.

17.

Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap.

Locke FL, Anasetti C; Moffitt Immunotherapy Working Group and the Immune Cell Therapy (ICE-T) Program.

J Immunother Cancer. 2017 Jul 18;5(1):59. doi: 10.1186/s40425-017-0265-y.

18.

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):753-758. doi: 10.1016/j.clml.2017.06.003. Epub 2017 Jun 16.

19.

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M.

J Clin Oncol. 2017 Sep 10;35(26):3002-3009. doi: 10.1200/JCO.2017.72.8428. Epub 2017 Jun 23. Erratum in: J Clin Oncol. 2019 Feb 20;37(6):528.

20.

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J.

Bone Marrow Transplant. 2017 Jul;52(7):1003-1009. doi: 10.1038/bmt.2017.63. Epub 2017 Apr 3.

PMID:
28368376
21.

Diagnosis and Management of Leukemic and Lymphomatous Meningitis.

Murthy H, Anasetti C, Ayala E.

Cancer Control. 2017 Jan;24(1):33-41. Review.

PMID:
28178710
22.

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C.

Haematologica. 2017 May;102(5):948-957. doi: 10.3324/haematol.2016.153072. Epub 2017 Jan 19.

23.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17. Review.

24.

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaai8269. doi: 10.1126/scitranslmed.aai8269.

25.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C.

Biol Blood Marrow Transplant. 2017 Mar;23(3):405-411. doi: 10.1016/j.bbmt.2016.12.624. Epub 2016 Dec 19.

26.

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C.

Bone Marrow Transplant. 2017 Apr;52(4):627-629. doi: 10.1038/bmt.2016.330. Epub 2016 Dec 19. No abstract available.

27.

Identification of DPB1 Permissive Unrelated Donors Is Highly Likely.

Tram K, Stritesky G, Wadsworth K, Ng J, Anasetti C, Dehn J.

Biol Blood Marrow Transplant. 2017 Jan;23(1):81-86. doi: 10.1016/j.bbmt.2016.10.021. Epub 2016 Oct 29.

28.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
29.

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2117-2125. doi: 10.1016/j.bbmt.2016.09.013. Epub 2016 Sep 19. Review.

30.

Regulatory T-Cell Therapy for Graft-versus-host Disease.

Heinrichs J, Bastian D, Veerapathran A, Anasetti C, Betts B, Yu XZ.

J Immunol Res Ther. 2016;1(1):1-14. Epub 2016 Apr 28.

31.

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, Horowitz MM, Anasetti C.

JAMA Oncol. 2016 Dec 1;2(12):1583-1589. doi: 10.1001/jamaoncol.2016.2520.

32.

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.

Mishra A, Anasetti C.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S49-52. doi: 10.1016/j.clml.2016.02.023. Review.

PMID:
27521324
33.

CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice.

Heinrichs J, Li J, Nguyen H, Wu Y, Bastian D, Daethanasanmak A, Sofi MH, Schutt S, Liu C, Jin J, Betts B, Anasetti C, Yu XZ.

Oncoimmunology. 2016 Mar 28;5(6):e1146842. doi: 10.1080/2162402X.2016.1146842. eCollection 2016 Jun.

34.

Predicting relevant immunogenetic disparities.

Pidala J, Anasetti C.

Blood. 2016 Jul 7;128(1):12-3. doi: 10.1182/blood-2016-05-717512. No abstract available.

35.

New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?

Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML.

Bone Marrow Transplant. 2016 Sep;51(9):1256-8. doi: 10.1038/bmt.2016.105. Epub 2016 Apr 18. No abstract available.

PMID:
27088383
36.

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.

Burns LJ, Logan BR, Chitphakdithai P, Miller JP, Drexler R, Spellman S, Switzer GE, Wingard JR, Anasetti C, Confer DL; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1108-1116. doi: 10.1016/j.bbmt.2016.02.018. Epub 2016 Mar 21.

37.

T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.

Fu J, Wu Y, Nguyen H, Heinrichs J, Schutt S, Liu Y, Liu C, Jin J, Anasetti C, Yu XZ.

J Immunol. 2016 Apr 1;196(7):3168-79. doi: 10.4049/jimmunol.1501020. Epub 2016 Feb 22.

38.

Biomarkers for GVHD prognosis.

Betts B, Anasetti C, Pidala J.

Lancet Haematol. 2015 Jan;2(1):e4-5. doi: 10.1016/S2352-3026(14)00040-4. Epub 2014 Dec 23. No abstract available.

PMID:
26687427
39.

Use of alternative donors for allogeneic stem cell transplantation.

Anasetti C.

Hematology Am Soc Hematol Educ Program. 2015;2015:220-4. doi: 10.1182/asheducation-2015.1.220. Review.

PMID:
26637725
40.

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen M.

Blood. 2016 Jan 14;127(2):260-7. doi: 10.1182/blood-2015-08-663823. Epub 2015 Nov 2.

41.

Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma.

Locke FL, Menges M, Nishihori T, Nwoga C, Alsina M, Anasetti C.

Bone Marrow Transplant. 2016 Feb;51(2):291-4. doi: 10.1038/bmt.2015.239. Epub 2015 Oct 12. No abstract available.

42.

Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.

Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C; Blood and Marrow Transplant Clinical Trials Network Trial 0201.

Biol Blood Marrow Transplant. 2016 Feb;22(2):359-370. doi: 10.1016/j.bbmt.2015.09.013. Epub 2015 Sep 25.

43.

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.

Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2015 Nov;50(11):1487-9. doi: 10.1038/bmt.2015.192. Epub 2015 Aug 24. No abstract available.

44.

Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature.

Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2015 Oct;50(10):1388-92. doi: 10.1038/bmt.2015.168. Epub 2015 Jul 20. Review. No abstract available.

PMID:
26191951
45.

Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.

Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, Burns LJ, Dalal JD, Freytes CO, Gupta V, Inamoto Y, Lazarus HM, LeMaistre CF, Steinberg A, Szwajcer D, Wingard JR, Wirk B, Wood WA, Joffe S, Hahn TE, Loberiza FR, Anasetti C, Horowitz MM, Lee SJ.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1815-22. doi: 10.1016/j.bbmt.2015.06.004. Epub 2015 Jun 11.

46.

HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.

Li J, Heinrichs J, Haarberg K, Semple K, Veerapathran A, Liu C, Anasetti C, Yu XZ.

J Immunol. 2015 Jul 15;195(2):717-25. doi: 10.4049/jimmunol.1401250. Epub 2015 Jun 5.

47.

Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.

Locke FL, Menges M, Veerapathran A, Coppola D, Gabrilovich D, Anasetti C.

J Immunother Cancer. 2015 May 19;3:20. doi: 10.1186/s40425-015-0065-1. eCollection 2015.

48.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Haematologica. 2015 Jul;100(7):970-7. doi: 10.3324/haematol.2015.123588. Epub 2015 Apr 3.

49.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1074-82. doi: 10.1016/j.bbmt.2015.03.014. Epub 2015 Mar 21.

50.

Tolerance associated gene expression following allogeneic hematopoietic cell transplantation.

Pidala J, Bloom GC, Eschrich S, Sarwal M, Enkemann S, Betts BC, Beato F, Yoder S, Anasetti C.

PLoS One. 2015 Mar 16;10(3):e0117001. doi: 10.1371/journal.pone.0117001. eCollection 2015.

Supplemental Content

Loading ...
Support Center